Zhangzhou Pien Tze Huang Pharmaceutical

Pien Tze Huang’s flagship product—a traditional Chinese medicine with a history of nearly five centuries—has demonstrated significant efficacy in treating hepatitis and certain cancers in clinical practice. The company has several other approved herbal medicines for various indications such as acne vulgaris and hemorrhoids. Investigational drugs include a compound targeting FGFR2/FGFR3 in advanced malignancies currently in Phase I/II trials. The company’s main economic indicators have grown at over a ~20% annual compound rate for more than two decades; it remains the leading exporter of single-variety Chinese patent medicines from China.